Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Colorectal polyps and polypectomy surveillance

Gastroenterology and hepatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

Severe abdominal pain, tachycardia, fever, peritonism or free gas after polypectomy suggests perforation or post-polypectomy electrocoagulation injury and needs urgent hospital assessment. Ongoing large-volume rectal bleeding, syncope or haemodynamic compromise requires acute lower-GI haemorrhage care, reversal planning and endoscopic, radiological or surgical haemostasis. A routine surveillance interval is irrelevant until the complication is stabilised.

Synopsis

Characterise colorectal polyps accurately, secure complete and safe excision, interpret pathology and procedural quality together, and apply UK post-polypectomy surveillance without unnecessary colonoscopy.

  • A polyp is a morphological finding, not a final diagnosis. Management depends on size, site, morphology, optical pattern, histology, number and confidence of complete removal.
  • Premalignant colorectal polyps include conventional adenomas and serrated lesions; small distal hyperplastic polyps generally carry different risk from proximal dysplastic serrated disease.
  • Suspected deep submucosal invasion should be photographed, described, biopsied selectively and referred for colorectal multidisciplinary planning rather than fragmented piecemeal removal.
  • A large non-pedunculated lesion without clear deep invasion should be assessed by an endoscopist skilled in advanced resection before surgery is assumed necessary.
  • The BSG high-risk criteria are either at least two premalignant polyps with one advanced polyp, or at least five premalignant polyps; this group receives a one-off colonoscopy at three years.
  • An advanced polyp for these criteria is a serrated polyp at least 10 mm or with any dysplasia, or an adenoma at least 10 mm or with high-grade dysplasia.
  • Piecemeal endoscopic mucosal resection of a lesion at least 20 mm needs an early site check, usually at two to six months, and a further check around eighteen months under BSG guidance.
  • Surveillance recommendations assume a high-quality complete baseline colonoscopy and credible excision; poor preparation, an incomplete examination or uncertain margins first requires completion or site assessment.

Key red flags

Deep invasion signal

Ulceration, induration, convergence, depressed morphology, disrupted vascular pattern or convincing non-lifting raises submucosal cancer and should prevent casual piecemeal resection.

Post-polypectomy complication

Immediate or delayed bleeding, escalating abdominal pain, fever, tachycardia or peritonism after resection raises haemorrhage, perforation or electrocoagulation syndrome and needs acute reassessment.

Investigation priorities

01
High-quality colonoscopyFirst step

Detect synchronous lesions, document caecal completion and bowel preparation, and permit complete optical characterisation and resection.

Management branches

At colonoscopyDescribe before removing

A colorectal polyp is identified during screening or symptomatic investigation.

  1. Record exact segment, calibrated size, morphology and optical pattern, photograph the lesion and inspect for synchronous disease before choosing treatment.
  2. Remove a lesion with an evidence-based technique within competence, retrieving tissue and documenting en-bloc versus piecemeal excision and confidence of completeness.
  3. For a large non-pedunculated lesion or possible superficial cancer, seek advanced endoscopy review; for likely deep invasion, avoid destructive fragmentation and refer to colorectal MDT.
  4. Place a tattoo only when useful for later localisation and at an appropriate distance and orientation, recording it precisely so it does not compromise subsequent resection.

Key medicines

Bowel-cleansing preparationUse the locally selected split-dose regimen with timing matched to the procedure, adjusting formulation and fluid advice for kidney, cardiac and electrolyte risk.Check obstruction, frailty, swallowing and aspiration risk, renal function and interacting medicines. Inadequate preparation invalidates surveillance assumptions and usually requires planned early repeat rather than reassurance.
Antithrombotic interruption planAlter aspirin, P2Y12 inhibitor, warfarin or direct oral anticoagulant only using the current BSG and local procedure-risk schedule for the individual's thrombotic indication.Do not give generic stop dates without renal function and indication review. High-thrombotic-risk cases need specialist ownership, and every interruption requires an explicit restart plan after haemostasis.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • BSG ACPGBI PHE polyp surveillance guidelineHigh-risk definitions, three-year surveillance, post-cancer and stopping principles.
  • BSG large non-pedunculated polyp guidelineOptical assessment, referral, endoscopic resection, tattooing and piecemeal EMR site checks.
  • BSG serrated polyp position statementRecognition, resection and surveillance implications of the serrated pathway.
  • BSG antithrombotic endoscopy guidelineProcedure bleeding risk, antithrombotic interruption and resumption planning.
  • NICE NG151 colorectal cancerCancer staging and multidisciplinary management when invasive malignancy is found.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom